“Efficacy and Safety of IL-5 Pathway-Targeting Biologics (Mepolizumab, Reslizumab, Benralizumab) in the Management of Hypereosinophilic Syndromes: A Systematic Review and Meta-Analysis”, OAIJMR, vol. 5, no. 5, pp. 607–626, Sep. 2025, doi: 10.37275/oaijmr.v5i5.780.